Dr Hal Barron

Dr Hal Barron - download image (JPG)

Hal joined GSK as Chief Scientific Officer and President, R&D on 1 January 2018. He is a member of the Board and the Corporate Executive Team.

His previous role was President, R&D at Calico (California Life Company). Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer.

Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.

Hal is Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco. He is also a Non-Executive Board Director of GRAIL, Inc, an early cancer detection healthcare company and a member of the Advisory Board of Verily Life Sciences LLC, a subsidiary of Alphabet Inc.

Hal holds a Bachelor of Science degree in Physics from Washington University in St. Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.

He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.